In the Day of Rare Diseases, we want to share the excellent news of Orphan Drug designation by the EMA of the novel nanomedicine developed in Smart4Fabry project. This nanomedicine, based on peptide targeted nanoliposomes containing alpha-galactosidase A is formulated with our DELOS nanoformulation platform. Nanomol Technologies team has optimized, scaled-up and produced the required batches for regulatory preclinical testing using a Quality by Design approach. In the video below the project coordinator Nora Ventosa from CIBER-BBN and one of our founders summarizes this achievement.
Excellent results for an excellent international teamwork! INSTITUT DE CIÈNCIA DE MATERIALS DE BARCELONA (ICMAB-CSIC), CIBER-BBN, Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca, IQAC-CSIC, Leanbio, DDR drug Development and Regulation, Technion - Israel Institute of Technology, Aarhus University, Joanneum Research, BNN-Bionanonet, Biokeralty and Covance.